Document is current
Any future updates will be listed below
-
Authors
Liu, Yang https://orcid.org/0000-0002-6023-3776
Ritchie, Scott C. https://orcid.org/0000-0002-8454-9548
Teo, Shu Mei
Ruuskanen, Matti O.
Kambur, Oleg
Zhu, Qiyun
Sanders, Jon
Vázquez-Baeza, Yoshiki
Verspoor, Karin https://orcid.org/0000-0002-8661-1544
Jousilahti, Pekka
Lahti, Leo
Niiranen, Teemu
Salomaa, Veikko https://orcid.org/0000-0001-7563-5324
Havulinna, Aki S. https://orcid.org/0000-0002-4787-8959
Knight, Rob
Méric, Guillaume https://orcid.org/0000-0001-6288-9958
Inouye, Michael https://orcid.org/0000-0001-9413-6520
- License Information
-
More Information
Article History
Received: 11 August 2023
Accepted: 13 February 2024
First Online: 25 March 2024
Competing interests
: V.S. has had research collaboration with Bayer Ltd (outside the present study). T.N. has received speaking honoraria from Servier Finland and AstraZeneca (not related to the present study). M.I. is a trustee of the Public Health Genomics (PHG) Foundation and a member of the Scientific Advisory Board of Open Targets and has research collaborations with AstraZeneca, Nightingale Health and Pfizer (not related to the present study). The other authors declare no competing interests.
